Prognosticators of survival in patients with metastatic pancreatic cancer and ascites

Identification of factors associated with survival after ascites diagnosis in metastatic pancreatic cancer (mPC) patients may guide treatment decisions and help to maintain quality of life (QoL) in this highly symptomatic patient collective. All patients treated for mPC at the Medical University of...

Full description

Saved in:
Bibliographic Details
Published in:ESMO open 2023-12, Vol.8 (6), p.102048-102048, Article 102048
Main Authors: Berger, Julia M., Alany, Ashly, Berchtold, Luzia, Puhr, Mag. Rainer, Friedrich, Alexander, Scheiner, Bernhard, Prager, Gerald W., Preusser, Matthias, Berghoff, Anna S., Bergen, Elisabeth S.
Format: Article
Language:English
Subjects:
ascites
Ascites - etiology
Ascites - pathology
Humans
liver metastases
Liver Neoplasms - drug therapy
metastatic pancreatic cancer
Original Research
Pancreatic Neoplasms - drug therapy
peritoneal carcinomatosis
Quality of Life
Retrospective Studies
systemic inflammation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Identification of factors associated with survival after ascites diagnosis in metastatic pancreatic cancer (mPC) patients may guide treatment decisions and help to maintain quality of life (QoL) in this highly symptomatic patient collective. All patients treated for mPC at the Medical University of Vienna between 2010 and 2019 developing ascites throughout their course of disease were identified by retrospective chart review. General risk factors, metastatic sites, systemic inflammation and liver function parameters, as well as type of treatment after ascites diagnosis were investigated for associations with survival. 117 mPC patients with ascites were included in this study. Median time from mPC to ascites diagnosis was 8.9 months (range 0 to 99) and median overall survival (OS) after ascites diagnosis was 27.4 days (range 21.3 to 42.6). Identified prognostic factors at ascites diagnosis independently associated with an impaired OS were presence of liver metastases (HR: 2.07, CI: 1.13-3.79, p=0.018), peritoneal carcinomatosis (HR: 1.74, CI: 1.11-2.71, p=0.015), and portal vein obstruction (PVO) (HR: 2.52, CI: 1.29-4.90, p=0.007). Compared to best supportive care (BSC), continuation of systemic therapy after ascites diagnosis was independently associated with survival (HR: 0.35, CI: 0.20-0.61, p
ISSN:2059-7029
2059-7029
DOI:10.1016/j.esmoop.2023.102048